This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Apstein refers to the Dutch GIPS 1 study as the "benchmark study" of GIK, yet this trial failed to demonstrate a significant benefit of GIK infusion in all randomized patients.¹ Similarly, a presentation of the recently completed Dutch GIPS 2 study indicated no benefit of GIK on mortality or infarct size in patients with AMI treated early with primary PCI; in fact, the trial was stopped early by the safety monitoring committee because of a potentially higher mortality in the GIK group.² These data are entirely consistent with the results of CREATE-ECLA,³ which was conducted largely in South America, India, and China, and suggest that interpretation of such trials should be based on their own relative merits, including internal and external validity, rather than on where the trial was conducted.

With regard to the timing of GIK administration, it is noteworthy that in the previous generation of . . . [Full Text of this Article]

Shamir R. Mehta, MD, MSc
smehta@mcmaster.ca

Salim Yusuf, MBBS, DPhil
McMaster University and Population Health Research Institute
Hamilton, Ontario

Rafael Diaz, MD; Ernesto Paolasso, MD
Estudios Cardiologicos Latinoamerica (ECLA)
Rosario, Argentina
for the CREATE-ECLA Steering Committee

RELATED ARTICLES

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Carl S. Apstein
JAMA. 2005;293(21):2596-2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Leonard A. Cobb, Thomas Killip, Costas T. Lambrew, Bruce A. MacLeod, Charles E. Rackley, Harry P. Selker, and Robert J. Zalenski
JAMA. 2005;293(21):2597.
EXTRACT | FULL TEXT  

Glucose-Insulin-Potassium Infusion and Mortality in the CREATE-ECLA Trial
Jayant Dey, Lawrence Blonde, Alan Burshell, Peggy Bolton, and Anita Richard
JAMA. 2005;293(21):2597-2598.
EXTRACT | FULL TEXT  

Effect of Glucose-Insulin-Potassium Infusion on Mortality in Patients With Acute ST-Segment Elevation Myocardial Infarction: The CREATE-ECLA Randomized Controlled Trial
The CREATE-ECLA Trial Group Investigators*
JAMA. 2005;293(4):437-446.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Glucose, insulin, and acute myocardial infarction: reply
Goyal et al.
Eur Heart J 2006;27:2142-2143.
FULL TEXT